Skip to main content

Table 2 Incidence rates of HZ (per 1000 persons - year) by age groups and IC condition in the Valencia Region in 2009–2014

From: Herpes zoster risk and burden of disease in immunocompromised populations: a population-based study using health system integrated databases, 2009–2014

IC condition

Incidence rate of HZ per 1000 PY (95% CI)

18–29

30–39

40–49

50–59

60–69

70–79

≥ 80

Overall

Population

2.32 (2.27–2.37)

2.46 (2.42–2.51)

2.93 (2.88–2.98)

5.88 (5.80–5.96)

8.63 (8.53–8.74)

9.82 (9.69–9.95)

10 (9.83–10.16)

5.02 (4.99–5.04)

IC-free cohort

2.26 (2.21–2.31)

2.36 (2.32–2.41)

2.75 (2.70–2.80)

5.52 (5.44–5.61)

8.12 (8.01–8.23)

9.29 (9.15–9.43)

9.54 (9.36–9.71)

4.64 (4.61–4.67)

IC-cohort

3.61 (3.33–3.91)

4.28 (4.02–4.54)

5.52 (5.26–5.79)

9.55 (9.22–9.90)

12.42 (12.05–12.80)

12.93 (12.54–13.33)

12.69 (12.21–13.29)

9.15 (9.02–9.29)

HSCT

42.37 (21.89–74.02)

38.94 (24.11–59.53)

50.13 (35.81–68.26)

69.24 (54.08–87.33)

61.82 (47.5–79.1)

51.99 (24.93–95.61)

0

56.07 (48.86–64.04)

SOT

6 (3.61–9.37)

6.23 (4.58–8.29)

7.31 (5.83–9.05)

14.89 (12.87–17.14)

17.02 (14.93–19.32)

14.21 (12.06–16.62)

17.26 (13.83–21.29)

12.65 (11.8–13.54)

HN

4.96 (4.1–5.94)

4.53 (3.77–5.41)

5.86 (4.97–6.87)

13.95 (12.5–15.52)

18.03 (16.46–19.7)

20.06 (18.37–21.85)

18.44 (16.46–20.6)

11.99 (11.48–12.52)

SON

3.87 (2.59–5.56)

4.94 (4.1–5.9)

5.84 (5.25–6.49)

10.24 (9.66–10.85)

12.27 (11.76–12.80)

12.12 (11.64–12.62)

12 (11.43–12.59)

10.97 (10.73–11.22)

NEOPLASIAS

4.64 (3.92–5.45)

4.71 (4.14–5.33)

5.86 (5.36–6.40)

10.70 (10.16–11.26)

12.86 (12.40–13.40)

12.91 (12.43–13.39)

12.53 (11.98–13.11)

11.01 (10.79–11.23)

HIV

11.9 (8.08–16.89)

12.34 (10.28–14.7)

13.44 (11.96–15.06)

12.8 (10.65–15.27)

13.99 (9.9–19.2)

11.38 (5.68–20.36)

3.87 (0.1–21.56)

12.94 (11.95–13.99)

AUTOIMMUNE

3.35 (3.05–3.67)

3.9 (3.62–4.2)

4.7 (4.4–5.01)

8.97 (8.54–9.42)

12.41 (11.87–12.98)

13.98 (13.32–14.66)

13.34 (12.45–14.27)

7.88 (7.71–8.05)

RA

4.19 (2.74–6.14)

5.34 (4.1–6.83)

6.03 (5.04–7.16)

10.22 (9.11–11.42)

13.88 (12.65–15.2)

14.3 (13–15.7)

13.71 (12.05–15.53)

11.05 (10.52–11.59)

SLE

9.76 (5.33–16.37)

8.62 (5.93–12.1)

8.37 (6.01–11.36)

17.2 (13.27–21.92)

20.37 (15.07–26.94)

21.8 (14.81–30.94)

19.63 (10.73–32.93)

13.36 (11.75–15.14)

IBD

4.83 (3.66–6.25)

4.6 (3.78–5.56)

5.16 (4.31–6.12)

9.65 (8.3–11.16)

13.4 (11.59–15.4)

12.97 (11.01–15.18)

16.21 (13.21–19.67)

8.29 (7.77–8.84)

PSORIASIS

2.97 (2.63–3.34)

3.37 (3.03–3.74)

3.74 (3.37–4.14)

7.55 (6.98–8.16)

10.39 (9.65–11.16)

12.4 (11.41–13.44)

11.11 (9.72–12.64)

6.13 (5.92–6.34)

MS

5.48 (2.51–10.4)

4.39 (2.75–6.64)

4.13 (2.67–6.09)

7.22 (4.87–10.31)

12.34 (8.33–17.62)

10.96 (5.47–19.62)

12.15 (2.51–35.51)

6.33 (5.29–7.51)

AT

1.35 (0.37–3.47)

2.07 (1.1–3.55)

4.21 (2.88–5.94)

10 (7.9–12.5)

11.06 (8.42–14.27)

13.56 (9.64–18.54)

17.97 (10.82–28.06)

7.19 (6.31–8.15)

  1. CI Confidence interval, IC immunocompromised, HSCT haematopoietic stem cell transplant, SOT solid organ transplantation, HN haematological neoplasia, SON solid organ neoplasia, NEOPLASIAS neoplasias overall, HIV human immunodeficiency virus, AUTOIMMUNE RA rheumatoid arthritis, SLE systemic lupus erythematosus, IBD Inflammatory bowel disease, MS multiple sclerosis, AT autoimmune thyroiditis, AUTOIMMUNE immunodeficiency disorders and autoimmune diseases overall (See supplementary Table 1)
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us